METHODS FOR TREATING CROHN'S DISEASE WITH THE SPECIFIC ANTI-IL23 ANTIBODY

Claims

One method for treating Crohn's disease in a patient administers a specific IL-23 antibody, e.g., guselkumab, at an initial intravenous dose and subsequent subcutaneous doses to enable the patient to respond to the antibody and meet one or more clinical endpoints.

1. A method for treating moderately to severely active Crohn's disease in a patient, comprising administering to the patient an antibody to IL-23, wherein the antibody comprises a light chain variable region and a heavy chain variable region, said light chain variable region comprising: a light chain amino acid sequence of the complementarity-determining region 1 (CDRL1) of sequence ident. no. 4; an amino acid sequence of CDRL2 of sequence ident. no. 5; and an amino acid sequence of CDRL3 of sequence ident. no. 6, said heavy chain variable region comprising: a heavy chain amino acid sequence of the complementarity-determining region 1 (CDRH1) of sequence ident. no. 1; an amino acid sequence of CDRH2 of sequence ident. no. 2; and an amino acid sequence of the CDRH3 of the sec. with ident. no.3, wherein the antibody is administered in an initial intravenous dose, an intravenous dose 4 weeks after the initial treatment, an intravenous dose 8 weeks after the initial treatment, and a subcutaneous dose every 4 or 8 weeks after the dose at 8 weeks, and wherein the patient is a responder to the antibody as measured 12 or 48 weeks after the initial intravenous dose.